1. Home
  2. VNDA vs TWN Comparison

VNDA vs TWN Comparison

Compare VNDA & TWN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VNDA
  • TWN
  • Stock Information
  • Founded
  • VNDA 2002
  • TWN 1986
  • Country
  • VNDA United States
  • TWN Hong Kong
  • Employees
  • VNDA N/A
  • TWN N/A
  • Industry
  • VNDA Biotechnology: Pharmaceutical Preparations
  • TWN Trusts Except Educational Religious and Charitable
  • Sector
  • VNDA Health Care
  • TWN Finance
  • Exchange
  • VNDA Nasdaq
  • TWN Nasdaq
  • Market Cap
  • VNDA 261.7M
  • TWN 193.5M
  • IPO Year
  • VNDA 2006
  • TWN N/A
  • Fundamental
  • Price
  • VNDA $4.63
  • TWN $42.34
  • Analyst Decision
  • VNDA Strong Buy
  • TWN
  • Analyst Count
  • VNDA 3
  • TWN 0
  • Target Price
  • VNDA $15.33
  • TWN N/A
  • AVG Volume (30 Days)
  • VNDA 424.4K
  • TWN 20.1K
  • Earning Date
  • VNDA 07-30-2025
  • TWN 01-01-0001
  • Dividend Yield
  • VNDA N/A
  • TWN 1.10%
  • EPS Growth
  • VNDA N/A
  • TWN N/A
  • EPS
  • VNDA N/A
  • TWN N/A
  • Revenue
  • VNDA $201,351,000.00
  • TWN N/A
  • Revenue This Year
  • VNDA $16.86
  • TWN N/A
  • Revenue Next Year
  • VNDA $39.78
  • TWN N/A
  • P/E Ratio
  • VNDA N/A
  • TWN N/A
  • Revenue Growth
  • VNDA 13.37
  • TWN N/A
  • 52 Week Low
  • VNDA $3.81
  • TWN $25.22
  • 52 Week High
  • VNDA $6.75
  • TWN $41.51
  • Technical
  • Relative Strength Index (RSI)
  • VNDA 60.49
  • TWN 85.80
  • Support Level
  • VNDA $4.49
  • TWN $37.08
  • Resistance Level
  • VNDA $4.72
  • TWN $38.26
  • Average True Range (ATR)
  • VNDA 0.14
  • TWN 0.69
  • MACD
  • VNDA 0.04
  • TWN 0.31
  • Stochastic Oscillator
  • VNDA 73.02
  • TWN 97.48

About VNDA Vanda Pharmaceuticals Inc.

Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.

About TWN Taiwan Fund Inc. (The)

Taiwan Fund Inc is a diversified closed-end management investment company. Its investment objective is to seek long-term capital appreciation through investment predominantly in equity securities listed in Taiwan stock exchange and the Republic of China. In selecting the companies for investments fund's portfolio managers will consider overall growth prospects, competitive position in the respective industry technology, research, and development, productivity, profit margins, return on investment, capital resources, government regulation, management and other factors.

Share on Social Networks: